Thiazolone linoyl-N-arylbenzamide compounds substituted with alkynyl groups and preparation methods and applications thereof
By developing thiazolyl-N-arylbenzamide compounds that replace alkynyl, the shortcomings of existing osteosarcoma treatment methods for high metastasis and recurrence are solved, and the significant inhibitory activity on a variety of tumor cells is achieved. , provides new drug options for treating osteosarcoma.
Patent Information
- Application Number
- CN202010971434.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-09-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing osteosarcoma treatment methods have limited effect on osteosarcoma patients with high metastasis and recurrence rates. Target treatment has not significantly improved survival rates. The lack of effective compounds has a significant inhibitory activity on osteosarcoma cells.
A substituted alkynyl thiazolyl-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof was developed, synthesized by Sonogashira coupling reaction and other chemical steps to inhibit the proliferation of tumor cells, Migration, infiltration, metastasis and recurrence.
This compound has shown significant inhibitory activity on a variety of tumor cells, including osteosarcoma, lung cancer, leukemia and pancreatic cancer cells, and has potential application value in the treatment of diseases such as osteosarcoma.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of synthetic medicine and biomedicine, and mainly relates to a preparation method and application of a thiazolone linoyl-N-aryl benzamide compound or a pharmaceutically acceptable salt thereof substituted with an alkynyl group. Background Art
[0002] Osteosarcoma, also known as osteogenic sarcoma, is a common malignant bone tumor that occurs in adolescents or children under the age of 20. [1] According to epidemiological studies on osteosarcoma, it is the most common bone malignancy in children, accounting for about 5% of pediatric tumors. Osteosarcoma is still a malignant tumor with a high mortality rate in children and adolescents, second only to lymphoma and brain cancer, but early detection and timely treatment have greatly improved the survival rate of the disease.
[0003] Treatment methods for different types of osteosarcoma usually use combined medication after surgery. It is worth noting that the cancer metastasis rate of osteosarcoma patients is as high as 80%. Among patients with metastasis, 90% are lung metastases. The recurrence rate is 20-30%, and recurrence is possible in both in situ and in situ tissues. In addition, the survival rate after recurrence has not improved in the past few decades, despite adjustments such as increasing the dose, changing the number of times, and combining multiple chemotherapy drugs.
[0004] At present, the research on therapeutic targets for osteosarcoma mainly focuses on the cell surface receptor tyrosine kinase family (PTKs) and intracellular signaling targets. For these targets, the main therapeutic drugs are divided into three categories: 1) immunomodulators; 2) receptor tyrosine kinase inhibitors; 3) intracellular signaling pathway inhibitors. In addition, new targets and treatment options for osteosarcoma include NK-kB ligands, folic acid inhibitors, etc., but they are all in the experimental research stage. Summary of the invention
[0005] The inventors have noticed that in previous literature reports, compounds with a thiazolinone skeleton structure have various pharmacological activities, such as the compound represented by formula (III) having anti-inflammatory activity and the compound represented by formula (IV) having anti-AIDS activity:
[0006]
[0007] Prior to the present invention, there were no reports on the evaluation of osteosarcoma cell activity test for this type of framework. The inventors have discovered and proposed that this framework compound may produce a series of new compound molecules with significant structure and activity, which may provide a new source of compounds for biological activity screening.
[0008] The present invention provides a thiazolinyl-N-aryl benzamide compound or a pharmaceutically acceptable salt thereof substituted with an alkynyl group, comprising a 3-(3-(ethynylbenzene)-4-thiazolinone)-N-aryl benzamide compound or a pharmaceutically acceptable salt thereof as shown in formula (I), and a 3-(3-aryl-4-thiazolinone)-5-ethynyl-N-aryl benzamide compound or a pharmaceutically acceptable salt thereof as shown in formula (II).
[0009] Among them, the 3-(3-(ethynylbenzene)-4-thiazolinone)-N-arylbenzamide compound or pharmaceutically acceptable salt thereof represented by formula (I) has the following structure:
[0010]
[0011] in,
[0012] Ar is aryl, aromatic heterocycle, alkyl-substituted aryl, halogen-substituted aryl, alkyl-substituted heteroaryl, halogen-substituted heteroaryl, trifluoromethyl-substituted aryl, nitro-substituted aryl, decalinyl, furanyl, alkenyl, alkynyl, diphenylalkyl, di(4-bromophenyl)alkyl, trifluoromethyl-substituted heteroaryl, nitro-substituted heteroaryl; wherein the aromatic heterocycle and heteroaryl are selected from indole, benzotriazole, thiophene, furan, pyrrole, dilactam, piperazine, imidazole, oxazole, pyrazine, etc.;
[0013] R 1 is halogen, alkoxy, alkyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen, etc.;
[0014] R 2 is alkyl, hydrogen, etc.;
[0015] R 3 is halogen, alkoxy, alkyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen, etc.;
[0016] n=0;1;2;3;4;5;6.
[0017] Preferably,
[0018] Ar is aryl, aromatic heterocycle, C1-C10 alkyl substituted aryl, halogen substituted aryl, C1-C10 alkyl substituted heteroaryl, halogen substituted heteroaryl, trifluoromethyl substituted aryl, nitro substituted aryl, naphthylmethyl, furanyl, allyl, propargyl, diphenylmethyl, di(4-bromophenyl)methyl, trifluoromethyl substituted heteroaryl, nitro substituted heteroaryl; wherein the aromatic heterocycle and heteroaryl are selected from indole, benzotriazole, thiophene, furan, pyrrole, dilactam, piperazine, imidazole, oxazole, pyrazine;
[0019] R 1is halogen, C1-C10 alkoxy, methyl, ethyl, isopropyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen;
[0020] R 2 is methyl or hydrogen;
[0021] R 3 It is halogen, C1-C10 alkoxy, methyl, ethyl, isopropyl, nitro, cyano, trifluoromethyl, phenyl, or hydrogen.
[0022] n=1;2;3;4;5;6.
[0023] Among them, the 3-(3-aryl-4-thiazolinone)-5-ethynyl-N-arylbenzamide compound or pharmaceutically acceptable salt represented by formula (II) has the following structure:
[0024]
[0025] in,
[0026] Ar is aryl, aromatic heterocycle, alkyl-substituted aryl, halogen-substituted aryl, alkyl-substituted heteroaryl, halogen-substituted heteroaryl, trifluoromethyl-substituted aryl, nitro-substituted aryl, decalinyl, furanyl, alkenyl, alkynyl, diphenylalkyl, di(4-bromophenyl)alkyl, trifluoromethyl-substituted heteroaryl, nitro-substituted heteroaryl; wherein the aromatic heterocycle and heteroaryl are selected from indole, benzotriazole, thiophene, furan, pyrrole, dilactam, piperazine, imidazole, oxazole, pyrazine, etc.;
[0027] R 1 is halogen, alkoxy, alkyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen, etc.;
[0028] R 2 is alkyl, hydrogen, etc.;
[0029] n=0;1;2;3;4;5;6.
[0030] Preferably,
[0031] Ar is aryl, aromatic heterocycle, C1-C10 alkyl substituted aryl, halogen substituted aryl, C1-C10 alkyl substituted heteroaryl, halogen substituted heteroaryl, trifluoromethyl substituted aryl, nitro substituted aryl, naphthylmethyl, furanyl, allyl, propargyl, diphenylmethyl, di(4-bromophenyl)methyl, trifluoromethyl substituted heteroaryl, nitro substituted heteroaryl; wherein the aromatic heterocycle and heteroaryl are selected from indole, benzotriazole, thiophene, furan, pyrrole, bislactam, piperazine, imidazole, oxazole, pyrazine;
[0032] R 1is halogen, C1-C10 alkoxy, methyl, ethyl, isopropyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen;
[0033] R 2 Methyl or hydrogen.
[0034] n=1;2;3;4;5;6.
[0035] The 3-(3-(ethynylbenzene)-4-thiazolinone)-N-arylbenzamide compounds or 3-(3-aryl-4-thiazolinone)-5-ethynyl-N-arylbenzamide compounds or pharmaceutically acceptable salts thereof of the present invention include but are not limited to the following:
[0036] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-N-(4-N-pyrazolbutyl)benzamide;
[0037] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-N-(4-N-phenylpropyl)benzamide;
[0038] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-N-(4-N-phenylethyl)benzamide;
[0039] 3-(3-(2-methoxy-5-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0040] 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0041] 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)-N-(4-N-indolbutyl)benzamide;
[0042] 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)-N-(4-N-pyrazolbutyl)benzamide;
[0043] 3-(3-(2-methyl-5-ethynylbenzene)-4(5-methyl)-thiazolinone-yl)-N-(4-N-indolbutyl)benzamide;
[0044] 3-(3-(2-methoxyphenyl)-4-thiazolinone)-5-ethynyl-N-(4-phenylbutyl)benzamide;
[0045] 3-(3-(2-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0046] 3-(3-(2-ethynylphenyl)-4-thiazolinone)-5-fluoro-N-(4-phenylbutyl)benzamide;
[0047] 3-(3-(2-ethynylphenyl)-4-thiazolinone)-5-methyl-N-(4-phenylbutyl)benzamide;
[0048] 3-(3-(2-ethynylphenyl)-4-thiazolinone)-N-(4-(4-chloro)phenylbutyl)benzamide;
[0049] 3-(3-(2-ethynylphenyl)-4-thiazolinone)-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0050] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0051] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-5-fluoro-N-(4-phenylbutyl)benzamide;
[0052] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-5-methyl-N-(4-phenylbutyl)benzamide;
[0053] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-N-(4-(4-chloro)phenylbutyl)benzamide;
[0054] 3-(3-(3-ethynylphenyl)-4-thiazolinone)-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0055] 3-(3-(4-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0056] 3-(3-(4-ethynylphenyl)-4-thiazolinone)-5-fluoro-N-(4-phenylbutyl)benzamide;
[0057] 3-(3-(4-ethynylphenyl)-4-thiazolinone)-5-methyl-N-(4-phenylbutyl)benzamide;
[0058] 3-(3-(4-ethynylphenyl)-4-thiazolinone)-N-(4-(4-chloro)phenylbutyl)benzamide;
[0059] 3-(3-(4-ethynylphenyl)-4-thiazolinone)-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0060] 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0061] 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)-N-(4-benzopyrrolylbutyl)benzamide;
[0062] 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)-N-(4-carbazolylbutyl)benzamide;
[0063] 3-(3-(2-methyl-5-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0064] 3-(3-(2-methoxy-5-ethynylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0065] 3-(3-(2-methoxy-5-ethynylphenyl)-4-thiazolinone)-5-fluoro-N-(4-phenylbutyl)benzamide;
[0066] 3-(3-(2-methoxy-5-ethynylphenyl)-4-thiazolinone)-5-methyl-N-(4-phenylbutyl)benzamide;
[0067] 3-(3-(2-methoxy-5-ethynylphenyl)-4-thiazolinone)-N-(4-(4-chloro)phenylbutyl)benzamide;
[0068] 3-(3-(2-methoxy-5-ethynylphenyl)-4-thiazolinone)-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0069] 3-(3-phenyl-4-thiazolinone)-5-ethynyl-N-(4-phenylbutyl)benzamide;
[0070] 3-(3-phenyl-4-thiazolinone)-5-ethynyl-N-(4-(4-chloro)phenylbutyl)benzamide;
[0071] 3-(3-phenyl-4-thiazolinone)-5-ethynyl-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0072] 3-(3-(2-methoxyphenyl)-4-thiazolinone)-5-ethynyl-N-(4-(4-chloro)phenylbutyl)benzamide;
[0073] 3-(3-(2-methoxyphenyl)-4-thiazolinone-5-ethynyl-N-(4-(4-fluoro)phenylbutyl)benzamide.
[0074] In the present invention, the acid addition salt formed by the compound and an acid is hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, acetic acid, salicylic acid, tartaric acid, lactic acid, citric acid, methanesulfonic acid, p-toluenesulfonic acid, maleic acid, pyruvic acid or succinic acid.
[0075] The present invention also provides a pharmaceutical composition, which comprises the substituted alkynyl thiazolone-N-aryl benzamide compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0076] Wherein, the pharmaceutical composition is formulated into pills, capsules, creams, gels, excipients, injectable fluids, aerosols, syrups or transdermal patches.
[0077] The present invention also proposes the use of the thiazolone-N-arylbenzamide compounds or pharmaceutically acceptable salts or pharmaceutical compositions substituted with alkynyl groups in the preparation of drugs for preventing and / or treating tumors.
[0078] Among them, the substituted alkynyl thiazolone-N-arylbenzamide compound or pharmaceutically acceptable salt, or pharmaceutical composition can be used to inhibit the proliferation, growth, migration, infiltration, metastasis and recurrence of tumor cells, or promote the apoptosis of tumor cells.
[0079] Among them, the tumors include osteosarcoma, leukemia, pancreatic cancer, lung cancer, etc.
[0080] The osteosarcoma cells include SJSA-1 osteosarcoma cells, MNNG / HOS osteosarcoma cells, U-2-OS osteosarcoma cells, MG63 osteosarcoma cells, HOS osteosarcoma cells, and 143B osteosarcoma cells.
[0081] The lung cancer cells include A549 lung cancer cells.
[0082] The leukemia includes Jurkat leukemia cells.
[0083] The pancreatic cancer cells include PANC-1 pancreatic cancer cells.
[0084] The present invention provides a method for synthesizing a 3-(3-(ethynylbenzene)-4-thiazolinone)-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof as shown in formula (I), which specifically comprises the following steps, including the following four reaction formulas (A), (B), (C), and (D):
[0085]
[0086] In the first step, p-iodoaniline and trimethylsilyl acetylene are subjected to a Sonogashira coupling reaction to obtain p-trimethylsilyl ethynyl aniline, and then the trimethylsilyl group is removed with potassium carbonate to obtain the product p-ethynyl aniline.
[0087]
[0088] In the second step, p-ethynylaniline (10 mmol, 1.0 eq) and methyl 3-formaldehyde benzoate (10 mmol, 1.0 eq) were reacted under toluene reflux conditions for 30 minutes, at which time the corresponding imine compound was generated. The reaction system was then cooled to room temperature, and thioethanol (10 mmol, 1.0 eq) was added to continue refluxing. After reacting for 5 hours, the reaction system was cooled to room temperature, and the reaction was monitored by spot plate to complete. The ester compound was then separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1 to 1:1).
[0089]
[0090] In the third step, the ester compound (5 mmol, 1.0 eq) obtained in the second step and LiOH (5.25 mmol, 1.05 eq) were reacted in a solvent of methanol: water (4:1) at room temperature for 20 hours. The substrate was completely consumed by spot plate monitoring. After the reaction, the methanol in the solvent was removed by rotary evaporation, and the remaining reaction solution was poured into 50 mL of water, and 3N HCl was added dropwise for acidification. A large amount of white solid precipitated, and pH paper was used to monitor until pH = 1. The white solid was filtered out with a Buchner funnel, dissolved with ethyl acetate, dried over anhydrous sodium sulfate, and rotary evaporated to obtain the carboxylic acid product.
[0091]
[0092] In the fourth step, the carboxylic acid product (1.5mmol, 1.0eq) obtained in the third step and 1-hydroxybenzotriazole (i.e., HOBt, 3.0mmol, 2.0eq) were dissolved in 20mL tetrahydrofuran, and N,N-diisopropylethylamine (DIPEA, 4.5mmol, 3.0eq) was added under ice bath conditions. After stirring for 20 minutes, the compound amine was added and continued to stir for 10 minutes. Subsequently, the condensing agent 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI, 3mmol, 2.0eq) was added in batches. After reacting for two hours, the plate was monitored and the raw materials were completely consumed. An appropriate amount of saturated sodium bicarbonate was added to the reaction solution in sequence, washed with saturated brine, and extracted with ethyl acetate three times. The crude product obtained by rotary evaporation was finally obtained by column chromatography (petroleum ether: ethyl acetate = 3:1-1:1) to obtain the target product.
[0093] Among them, in reaction formula (A), (B), (C) and reaction formula (D), Ar, R 1, R 2 , R 3 The same as defined in formula (I).
[0094] The present invention also provides a method for synthesizing a 3-(3-aryl-4-thiazolinone)-5-ethynyl-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof as shown in formula (II), which specifically comprises the following steps, including the following four reaction formulas (E), (F), (G), and (H):
[0095]
[0096] In the first step, sodium borohydride is used to reduce a methyl ester group in methyl 5-iodoisophthalate to an alcohol, and then the alcohol is oxidized to an aldehyde under manganese dioxide conditions. The obtained compound undergoes a Sonogashira coupling reaction with trimethylsilyl acetylene to generate methyl 3-formaldehyde-5-trimethylsilylethynylbenzoate, and then potassium carbonate is used to remove the trimethylsilyl group to obtain the product methyl 3-formaldehyde-5-ethynylbenzoate.
[0097]
[0098] In the second step, substituted aniline (10 mmol, 1.0 eq) and methyl 3-formaldehyde-5-ethynylbenzoate (10 mmol, 1.0 eq) were reacted under toluene reflux conditions for 30 minutes, at which time the corresponding imine compound was generated. The reaction system was then cooled to room temperature, and thioethanol (10 mmol, 1.0 eq) was added to continue refluxing. After reacting for 5 hours, the reaction was cooled to room temperature, and the reaction was monitored by spot plate to complete. The ester compound was then separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1 to 1:1).
[0099]
[0100] In the third step, the ester compound (5 mmol, 1.0 eq) obtained in the second step and LiOH (5.25 mmol, 1.05 eq) were reacted in a solvent of methanol: water (4:1) at room temperature for 20 hours. The substrate was completely consumed by spot plate monitoring. After the reaction, the methanol in the solvent was removed by rotary evaporation, and the remaining reaction solution was poured into 50 mL of water, and 3N HCl was added dropwise for acidification. A large amount of white solid precipitated, and pH paper was used to monitor until pH = 1. The white solid was filtered out with a Buchner funnel, dissolved with ethyl acetate, dried over anhydrous sodium sulfate, and rotary evaporated to obtain the carboxylic acid product.
[0101]
[0102] In the fourth step, the carboxylic acid product (1.5mmol, 1.0eq) obtained in the third step and 1-hydroxybenzotriazole (i.e., HOBt, 3.0mmol, 2.0eq) were dissolved in 20mL tetrahydrofuran, and N,N-diisopropylethylamine (DIPEA, 4.5mmol, 3.0eq) was added under ice bath conditions. After stirring for 20 minutes, the compound amine was added and continued to stir for 10 minutes. Subsequently, the condensation agent 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI, 3mmol, 2.0eq) was added in batches. After two hours of reaction, the plate was monitored and the raw materials were completely consumed. An appropriate amount of saturated sodium bicarbonate was added to the reaction solution in sequence, washed with saturated brine, and extracted with ethyl acetate three times. The crude product obtained by rotary evaporation was finally obtained by column chromatography (petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain the target product.
[0103] Among them, in reaction formula (E), (F), (G) and reaction formula (H), Ar, R 1 , R 2 The definition of is the same as that of formula (II).
[0104] The beneficial effects of the present invention are as follows: the present invention discloses a thiazolone linoyl-N-aryl benzamide compound or a pharmaceutically acceptable salt thereof which has an inhibitory activity on tumor cells and can be used to treat osteosarcoma and other related diseases, and has important significance in the study of tumor diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0105] Figure 1 The product A-1 obtained in Example 1 1 H NMR ( Figure 1 A) and 13 C NMR ( Figure 1 B) Schematic diagram.
[0106] Figure 2 The product A-2 obtained in Example 2 1 H NMR ( Figure 2 A) and 13 C NMR ( Figure 2 B) Schematic diagram.
[0107] Figure 3 The product A-3 obtained in Example 3 1 H NMR ( Figure 3 A) and 13 C NMR ( Figure 3 B) Schematic diagram.
[0108] Figure 4 The product A-4 obtained in Example 4 1 H NMR ( Figure 4 A) and 13 C NMR ( Figure 4 B) Schematic diagram.
[0109] Figure 5 The product A-5 obtained in Example 5 1 H NMR ( Figure 5 A) and 13 C NMR ( Figure 5 B) Schematic diagram.
[0110] Figure 6 The product A-6 obtained in Example 6 1 H NMR ( Figure 6 A) and 13 C NMR ( Figure 6 B) Schematic diagram.
[0111] Figure 7 The product A-7 obtained in Example 7 1 H NMR ( Figure 7 A) and 13 C NMR ( Figure 7 B) Schematic diagram.
[0112] Figure 8 The product A-8 obtained in Example 8 1 H NMR ( Figure 8 A) and 13 C NMR ( Figure 8 B) Schematic diagram.
[0113] Fig. 9 The product A-9 obtained in Example 9 1 H NMR ( Fig. 9 A) and 13 C NMR ( Fig. 9 B) Schematic diagram.
[0114] Fig.10 The product A-10 obtained in Example 10 1 H NMR ( Fig.10 A) and 13 C NMR ( Fig.10 B) Schematic diagram. DETAILED DESCRIPTION
[0115] The present invention is further described in detail in conjunction with the following specific embodiments and drawings, and the protection content of the present invention is not limited to the following embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention and are protected by the attached claims.
[0116] The preparation methods of compounds 1-10 in the following examples of the present invention refer to the preparation of the compounds represented by formula (I) or formula (II) mentioned above. Determination method: low-resolution mass spectrometry (molecular weight) and nuclear magnetic resonance instrument (hydrogen spectrum and carbon spectrum).
[0117] Embodiment 1:
[0118]
[0119] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 1 As shown:
[0120] 1 H NMR(400MHz,Chloroform-d)δ7.78(d,J=6.4Hz,1H),7.57(d,J=7.8Hz,1H),7.42(t,J=6.2Hz,1H),7.29–7.05(m,9H),6.71–6.60(m,1H),6 .08(s,1H),3.92–3.75(m,3H),3.73–3.59(m,3H),3.40–3.20(m,2H),2.91(s,1H),2.57(q,J=7.0Hz,2H),1.56(dt,J=24.2Hz,7.6Hz,4H). 13 C NMR (100MHz, CDCl3) δ171.43,166.73,155.35,142.12,139.21,134.96,133.76,133.67,130.47,128.79,128.44,128.36,127.49 ,126.77,125.84,125.29,114.66,112.16,82.41,77.60,77.28,77.03,76.96,64.30,55.92,39.97,35.49,33.13,29.11,28.71.
[0121] Embodiment 2:
[0122]
[0123] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 2 As shown:
[0124] 1H NMR(400MHz,Chloroform-d)δ7.65(s,1H),7.52(s,1H),7.39(d,J=7.5Hz,1H),7.31–7.16(m,7H),7.11(t,J=7.2Hz,5H),3.95(d, J=15.7Hz,1H),3.82(d,J=15.9Hz,1H),3.36(d,J=6.1Hz,2H),2.96(s,1H),2.59(t,J=6.9Hz,3H),1.68–1.51(m,8H),1.26(s,2H).
[0125] 13 C NMR (101MHz, CDCl3) δ166.55,142.00,135.07,130.49,128.98,128.39,127. 42,125.89,82.64,78.13,40.02,35.47,31.44,30.20,29.71,29.16,28.70.
[0126] Embodiment 3:
[0127]
[0128] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 3 As shown:
[0129] 1 H NMR(400MHz,Chloroform-d)δ7.65(s,1H),7.52(d,1H),7.39(d,J=7.5Hz,1H),7.32–7.17(m,7H),7.10(q,J=12.3Hz,9.7Hz,6H),5.99(s,1H),3.95 (d,J=15.7Hz,1H),3.82(d,J=15.9Hz,1H),3.36(d,J=6.1Hz,2H),2.96(s ,1H),2.59(t,J=6.9Hz,3H),1.68–1.49(m,8H),1.26(s,2H),0.81(s,1H).
[0130] 13 C NMR (101MHz, CDCl3) δ169.35,135.89,134.45,130.13,128.59,128.27,127 .79,121.46,121.01,119.31,109.37,101.15,45.82,39.42,27.46,26.81.
[0131] Embodiment 4:
[0132]
[0133] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 4 As shown:
[0134] 1 H NMR(400MHz,Chloroform-d)δ7.63(s,1H),7.55(d,J=7.8Hz,1H),7.43(d,J=7.5Hz,1 H),7.38(d,J=7.5Hz,1H),7.22(dt,J=15.5Hz,8.1Hz,3H),7.11(t,J=7.4Hz,2H),7.06 –6.97(m,3H),6.77(t,J=8.3Hz,2H),6.70–6.50(m,3H),4.07(t,J=6.4Hz,3H),3.90–3 .72(m,3H),3.67(s,3H),3.27(q,J=6.1Hz,3H),1.83–1.75(m,3H),1.56–1.34(m,3H).
[0135] 13 C NMR (101MHz, CDCl3) δ170.37,165.69,156.32,153.80,150.25,138.39,13 4.93,133.80,129.48,127.86,127.47,126.69,126.30,125.61,124.88,1 24.78,120.46,120.01,118.30,116.28,116.04,115.03,114.80,111.76, 111.68,108.32,100.14,63.10,55.23,44.81,38.43,32.07,26.43,26.04.
[0136] Embodiment 5:
[0137]
[0138] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 5 As shown:
[0139] 1H NMR(400MHz,Chloroform-d)δ7.64(d,J=12.8Hz,1H),7.53(d,J=7.4Hz,0H),7.36(d,J =7.9Hz,1H),7.18(d,J=7.6Hz,3H),7.08(d,J=8.0Hz,4H),5.99(s,0H),4.18(q,J=7.4 Hz,1H),4.02(q,J=7.2Hz,1H),3.29(d,J=7.0Hz,2H),2.55(t,J=7.6Hz,2H),2.19–2.0 7(m,1H),1.93(d,J=10.2Hz,1H),1.67(d,J=6.9Hz,1H),0.79(q,J=10.0Hz,8.3Hz,1H).
[0140] 13 C NMR (101MHz, CDCl3) δ166.65,142.05,131.49,131.46,128.43,128.37,125.87,120.72,39.99,35.49,29.71,29.14,28.69,20.16,19.90.
[0141] Embodiment 6:
[0142]
[0143] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 6 As shown:
[0144] 1 H NMR(400MHz,Chloroform-d)δ7.66(d,J=9.4Hz,2H),7.62(s,1H),7.32–7.28(m, 2H),7.22–7.16(m,4H),6.93(d,J=7.7Hz,1H),6.88–6.79(m,2H),6.09(s,1H),5 .95(d,J=12.7Hz,1H),3.97(d,J=15.5Hz,1H),3.90(d,J=15.7Hz,1H),3.82(s,3 H),3.43(q,J=6.8Hz,2H),3.12(s,1H),2.66(t,J=7.4Hz,2H),1.71–1.61(m,4H).
[0145] 13C NMR (101MHz, CDCl3) δ171.32,165.84,154.80,141.95,140.50,135.25,133.89,130.60,129.89,128.39,126. 94,125.91,125.03,122.87,121.04,112.22,82.15,78.73,63.97,55.79,40.03,35.44,33.08,29.10,28.66.
[0146] Embodiment 7:
[0147]
[0148] Nuclear Magnetic Resonance 1 H NMR. 13 C NMR spectrum Figure 7 As shown:
[0149] 1 H NMR(400MHz,Chloroform-d)δ7.70(s,1H),7.58(d,J=7.6Hz,1H),7.43(d,J=7.8Hz,1H),7.36(t,2H),7.32–7.26(m,3H),7.24–7.12(m,5H),6.14(s,1H ),6.02(t,J=5.7Hz,1H),3.98(d,J=15.9Hz,1H),3.88(d,J=15.8Hz,1H),3. 45(q,J=6.7Hz,2H),3.04(s,1H),2.67(t,J=7.3Hz,2H),1.75–1.62(m,4H).
[0150] 13 C NMR (101MHz, CDCl3) δ171.32,165.84,154.80,141.95,140.50,135.25,133.89,130.60,129.89,128.39,126. 94,125.91,125.03,122.87,121.04,112.22,82.15,78.73,63.97,55.79,40.03,35.44,33.08,29.10,28.66.
[0151] Embodiment 8:
[0152]
[0153] Nuclear Magnetic Resonance 1 H NMR. 13 C NMR spectrum Figure 8 As shown:
[0154] 1 H NMR(400MHz,Chloroform-d)δ7.74(s,1H),7.61(d,J=7.1Hz,1H),7.42(s,1H),7 .32(s,2H),7.26(s,2H),7.21–7.15(m,2H),7.14–7.01(m,3H),6.95(s,1H),6.1 7(s,1H),6.06(s,1H),4.13–4.05(m,3H),3.88(d,J=15.8Hz,1H),3.76(d,J=15. 8Hz,1H),3.37–3.20(m,3H),2.99(s,1H),1.90–1.67(m,3H),1.56–1.42(m,3H).
[0155] 13 C NMR (101MHz, CDCl3) δ171.00,166.65,139.71,139.14,137.34,135.25,130.82,129.63,129.32,129.21,1 28.95,127.53,126.08,126.00,123.20,105.57,82.49,78.40,64.95,51.26,39.65,33.43,28.06,25.99.
[0156] Embodiment 9:
[0157]
[0158] Nuclear Magnetic Resonance 1 H NMR. 13 C NMR spectrum Fig. 9 As shown:
[0159] 1H NMR(400MHz,Chloroform-d)δ7.66(t,J=1.5Hz,1H),7.53(dt,J=7.6Hz,1.3Hz,1H),7.4 0(dt,J=7.6Hz,1.3Hz,1H),7.36–7.29(m,3H),7.29–7.24(m,2H),7.25–7.16(m,3H),7. 12(ddd,J=8.0Hz,2.0Hz,1.3Hz,1H),6.22(s,1H),6.11(s,1H),3.96(dd,J=15.9Hz,1.5 Hz,1H),3.85(d,J=15.9Hz,1H),3.75–3.64(m,2H),3.06(s,1H),2.91(t,J=6.9Hz,1H).
[0160] 13 C NMR (101MHz, CDCl3) δ170.94,166.63,139.89,138.81,137.35,135.42,130.85,129.73,129.22,128. 75,127.21,126.68,126.06,125.82,123.27,82.48,78.35,64.92,58.41,41.20,35.59,33.37,18.41.
[0161] Embodiment 10:
[0162]
[0163] Nuclear Magnetic Resonance 1 H NMR. 13 C NMR spectrum Fig.10 As shown:
[0164] 1 H NMR(400MHz,Chloroform-d)δ7.65(s,1H),7.49(d,J=7.7Hz,1H),7.39(d,J=7.8Hz,1H),7.35–7.22(m,5H),7.23–7.14(m,4H),7.12(d,J=8.1 Hz,1H),6.27(s,1H),6.10(s,1H),3.96(s,0H),3.81(s,0H),3.43(q,J=6.6Hz,2H),3.03(s,1H),2.68(t,J=7.5Hz,2H),1.92(p,J=7.2Hz,3H).
[0165] 13C NMR (101MHz, CDCl3) δ170.99,166.54,141.48,139.81,137.38,135.37,130.84,129.57,129.22,128.9 3,128.57,128.41,127.25,126.09,125.87,123.26,82.49,78.43,64.92,39.97,33.54,33.39,30.97.
[0166] Example 11: Anti-tumor cell activity test experiment:
[0167] 1. Inoculation of cells:
[0168] 1) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 SJSA-1 osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0169] 2) A single cell suspension was prepared using DMEM culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 MNNG / HOS osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0170] 3) A single cell suspension was prepared using McCoy'5A culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 U-2-OS osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0171] 4) A single cell suspension was prepared using DMEM culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 MG63 osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0172] 5) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 HOS osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0173] 6) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 143B osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0174] 7) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 A549 lung cancer cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0175] 8) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 Jurkat leukemia cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0176] 9) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 PANC-1 pancreatic cancer cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0177] 2. Administration: The compounds of formula (I) and (II) synthesized in the above examples of the present invention were prepared into a stock solution with a final concentration of 25 mM using DMSO, diluted to 1 uM using complete culture medium, and applied to cells in three replicate wells.
[0178] 3. Cultivation: Cultivate in an incubator with 5% CO2 and 37°C saturated humidity for 72 hours.
[0179] 4. Color development: After 72 hours of culture, aspirate the culture medium, add 100 μl complete culture medium and 10 μl CCK8 to each well, and incubate at 37°C for 4 hours.
[0180] 5. Colorimetry: Select 620nm and 450nm wavelengths, measure the optical density (OD) value of each well on the microplate reader, and record the results.
[0181] 6. For the same well, the absorbance value at 450nm minus the absorbance value at 620nm (background absorbance value) is used as the final absorbance and is substituted into the following formula.
[0182] 7. Cell proliferation activity (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100.
[0183] A (drug addition): absorbance of wells with osteosarcoma cells, CCK solution (Cell Counting Kit-8, a rapid and highly sensitive detection reagent for cell proliferation and cytotoxicity based on WST-8 (chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonylbenzene)-2H-tetrazolyl monosodium salt)) and drug solution (drug solution refers to DMSO solution of the compound sample to be tested)
[0184] A (blank): absorbance of wells with culture medium and CCK solution but no cells
[0185] A(0 drug addition): absorbance of the well with cells, CCK solution and no drug solution
[0186] 8. The experimental results show that: under the action of the compounds of formula (I) and (II) of the present invention at a concentration of 1 μM, the survival rates of 6 different subtypes of osteosarcoma cells are shown in Table 1. This shows that among the 10 compounds, 3 compounds A-2, A-6, and A-7 showed good inhibitory activity against osteosarcoma cells 143B, SJSA-1, and HOS; at the same time, these three compounds showed very good inhibitory activity against osteosarcoma cells MNNG / HOS and MG63.
[0187] Table 1
[0188]
[0189]
[0190] 9. The experimental results show that: under the action of the compounds of formula (I) and (II) of the present invention at a concentration of 1 μM, the survival rate of lung cancer cell A549 is shown in Table 2. This shows that among the 10 compounds, 3 compounds A-2, A-6, and A-7 exhibited good inhibitory activity against lung cancer cell A549.
[0191] Table 2
[0192]
[0193] 10. The experimental results show that: under the action of the compounds of formula (I) and (II) of the present invention at a concentration of 1 μM, the survival rate of the leukemia cell line Jurkat is shown in the following Table 3. This shows that among the 10 compounds, 5 compounds A-1, A-2, A-6, A-7, and A-8 exhibited good inhibitory activity against the leukemia cell Jurkat.
[0194] Table 3
[0195]
[0196] 11. The experimental results show that: under the action of the compounds of formula (I) and (II) of the present invention at a concentration of 1 μM, the survival rate of the pancreatic cancer cell line PANC-1 is shown in the following Table 4. This shows that among the 10 compounds, two compounds A-6 and A-7 exhibited better inhibitory activity against the pancreatic cancer cell line PANC-1.
[0197] Table 4
[0198]
[0199] The protection content of the present invention is not limited to the above embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention and are protected by the attached claims.
Claims
1. A thiazolone substituted alkynyl group N -Arylbenzamide compounds or pharmaceutically acceptable salts thereof, characterized in that: Selected from the following: 3-(3-(3-ethynylphenyl)-4-thiazolinone)- N -(4-phenylbutyl)benzamide; 3-(3-(2-methoxy-5-ethynylphenyl)-4-thiazolinone)- N -(4-phenylbutyl)benzamide; 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)- N -(4-phenylbutyl)benzamide; 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)- N -(4-N-indolylbutyl)benzamide; 3-(3-(2-methyl-4-ethynylphenyl)-4-thiazolinone)- N -(4-N-pyrazolylbutyl)benzamide; 3-(3-(3-ethynylphenyl)-4-thiazolinone)- N -(4-N-pyrazolylbutyl)benzamide; 3-(3-(3-ethynylphenyl)-4-thiazolinone)- N -(4-N-phenylpropyl)benzamide; 3-(3-(3-ethynylphenyl)-4-thiazolinone)- N -(4-N-phenylethyl)benzamide; 3-(3-(2-methyl-5-ethynylbenzene)-4(5-methyl)-thiazolinone)- N -(4-N-indolylbutyl)benzamide; 3-(3-(2-methoxyphenyl)-4-thiazolinone)-5-ethynyl- N -(4-phenylbutyl)benzamide.
2. The thiazolone lino-substituted alkynyl according to claim 1 N -Arylbenzamide compounds or pharmaceutically acceptable salts thereof, characterized in that: The acid addition salt formed by the compound and an acid; wherein the acid is hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, acetic acid, salicylic acid, tartaric acid, lactic acid, citric acid, methanesulfonic acid, p-toluenesulfonic acid, maleic acid, pyruvic acid or succinic acid.
3. A pharmaceutical composition, characterized in that It contains the thiazolone linoyl-substituted alkynyl group as claimed in claim 1 N - an aryl benzamide compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition according to claim 3, characterized in that The pharmaceutical composition is formulated into pills, capsules, creams, gels, excipients, injectable fluids, aerosols, syrups or transdermal patches.
5. The thiazolone lino-substituted alkynyl according to claim 1 N - Use of an arylbenzamide compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 3 or 4, in the preparation of a drug for preventing and / or treating tumors, wherein: The tumor is osteosarcoma, leukemia, or pancreatic cancer.
6. The use according to claim 5, characterized in that: The thiazolone linoyl group of the substituted alkynyl group N -Arylbenzamide compounds or pharmaceutically acceptable salts and derivatives thereof are used to inhibit the proliferation, growth, migration, infiltration, metastasis and recurrence of tumor cells, or promote apoptosis of tumor cells.
7. The use according to claim 5, characterized in that: The osteosarcoma cells are SJSA-1 osteosarcoma cells, MNNG / HOS osteosarcoma cells, U-2-OS osteosarcoma cells, MG63 osteosarcoma cells, HOS osteosarcoma cells, and 143B osteosarcoma cells; the leukemia cells are Jurkat leukemia cells; and the pancreatic cancer cells are PANC-1 pancreatic cancer cells.
